1[1]Perez EA, Lembersky B, Kaywin P, et al. Intravenous (Ⅳ) granisetron vs ondansetron in the prevention of cyclophosphamide-doxorubicin-induced emesis in breast cancer patients: a double blind crossover study. Proc Am Soc Clin Oncol,1996,15:543 (abstr. 1764)
2[2]Perez EA, Hesketh P, Sandbach J, et al. Comparison of single dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randimized parallel study. J Clin Oncol,1998, 16 (2): 754 ～ 760
3[3]Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin induced emesis. J Clin Oncol, 1995, 13 (5): 1242～ 1248
4[4]Gralla RJ, Navari RM, Hesketh PJ, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol, 1998, 16 (4): 1568～ 1573
5[5]The Italian group for antiemetic research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med,2000, 342 (21): 1554～1559
6[6]Crawfold J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (rmetHuG-CSF). N Engl J Med , 1991, 325 (3): 164 ～ 170
7[7]Maher D, Green M, Bishop J,et al. Randomized, placebo controlled trial of filgrastim (r-metHuG-CSF) in patients with febrile neutropenia ( FN ) following chemotherapy (CT). Proc Am Soc Clin Oncol, 1993, 12:434 (abstr.)
8[8]Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer, 1993, 29A (3):319 ～ 324
9[9]Gebbia V, Testa A, Valenza R, et al. A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother, 1993, 5 (3): 186 ～ 190
10[10]Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breasr cancer and lytic bone metastases. N Engl J Med, 1996,335 (24): 1785～ 1791
